On September 12, 2018 GEN inCode acquired the personalized medicine service of the products Cardio inCode®, Lipid inCode®, SudD inCode® and Thrombo inCode® and the assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, part of Ferrer Grupo, a large pharmaceutical and healthcare company based in Spain.
GEN inCode has a strong intellectual property portfolio with a vision to educate patients on cardiovascular risk the predictive capability of genomics and lifestyle choices to help improve patient outcomes.